We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

99 hedge funds and large institutions have $348M invested in Vanda Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 19

102% more call options, than puts

Call options by funds: $40.3M | Put options by funds: $20M

86% more capital invested

Capital invested by funds: $187M → $348M (+$160M)

86% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 14

13% more funds holding

Funds holding: 88 → 99 (+11)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
99
Holders Change
+11
Holders Change %
+12.5%
% of All Funds
3.21%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
26
Increased
44
Reduced
19
Closed
14
Calls
$40.3M
Puts
$20M
Net Calls
+$20.3M
Net Calls Change
+$8.83M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.3M
2
Wells Fargo
Wells Fargo
California
+$13.4M
3
PA
Perceptive Advisors
New York
+$9.28M
4
BBA
Baker Bros. Advisors
New York
+$8.81M
5
DM
Deerfield Management
New York
+$8.76M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$9.85M
2
NI
Numeric Investors
Massachusetts
-$7.95M
3
First Eagle Investment Management
First Eagle Investment Management
New York
-$7.88M
4
BIM
Bogle Investment Management
Massachusetts
-$3.94M
5
VM
VHCP Management
New York
-$3.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
BA
76
BlackRock Advisors
Delaware
$226K -$462K -43,203 -68%
VKH
77
Virtu KCG Holdings
New York
$214K +$208K +19,511 New
SO
78
STRS Ohio
Ohio
$213K +$112K +10,500 +118%
AIG
79
American International Group
New York
$208K -$4.69K -439 -2%
DekaBank Deutsche Girozentrale
80
DekaBank Deutsche Girozentrale
Germany
$203K +$198K +18,500 New
JG
81
Jefferies Group
New York
$198K +$193K +18,100 New
LMF
82
LMR Master Fund
Cayman Islands
$182K +$177K +16,582 New
PPA
83
Parametric Portfolio Associates
Washington
$153K +$2.66K +249 +2%
DTL
84
Dynamic Technology Lab
Singapore
$146K -$44.6K -4,176 -24%
Arrowstreet Capital
85
Arrowstreet Capital
Massachusetts
$143K +$139K +13,044 New
GGHC
86
Gilder Gagnon Howe & Co
New York
$130K +$6.88K +644 +6%
GCP
87
GSA Capital Partners
United Kingdom
$112K +$109K +10,212 New
AAP
88
Ardsley Advisory Partners
Connecticut
$110K – – –
FANJ
89
Financial Architects (New Jersey)
New Jersey
$110K – – –
SG Americas Securities
90
SG Americas Securities
New York
$105K +$103K +9,607 New
Citigroup
91
Citigroup
New York
$102K +$72.7K +6,804 +271%
MAA
92
Managed Account Advisors
New Jersey
$84K +$82K +7,676 New
TRCT
93
Tower Research Capital (TRC)
New York
$78K +$75K +7,016 +25,057%
EWM
94
Edge Wealth Management
New York
$38K +$16K +1,500 +75%
BlackRock
95
BlackRock
New York
$10K – – –
First Manhattan
96
First Manhattan
New York
$2K – – –
PFG
97
Piershale Financial Group
Illinois
$1K – – –
GC
98
Globeflex Capital
California
$1K +$1.03K +96 New
Manulife (Manufacturers Life Insurance)
99
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$245 +$1.09K +102 +0.5%
First Eagle Investment Management
100
First Eagle Investment Management
New York
– -$7.88M -975,000 Closed
1 2 3
4
5

VNDA Hedge Fund Activity: Q3 2013 in Review

99 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2013, worth a combined $348M — up 86% from $187M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new VNDA positions and 14 closed out — a net gain of 12 holders — while 44 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $25.3M. The largest seller was Consonance Capital Management, cutting an estimated $9.85M.

  • 99 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2013, up from 88 in Q2 2013.
  • Funds reported $348M of Vanda Pharmaceuticals stock for Q3 2013, up 86% quarter-over-quarter.
  • 26 funds opened new Vanda Pharmaceuticals positions in Q3 2013 and 14 closed out, a net change of +12 holders.
  • The largest Vanda Pharmaceuticals buyer in Q3 2013 was Fidelity Investments, an estimated $25.3M added.
  • The largest Vanda Pharmaceuticals seller in Q3 2013 was Consonance Capital Management, an estimated $9.85M sold.

Based on aggregated 13F filings for Q3 2013.